Dr. Bruce D. Forrest joins Skymount Medical as Chief Medical Officer, strengthening the team for future growth

Content of the article

Bruce D. Forrest, MD, MBA brings over 30 years of global leadership in pharmaceutical development

CALGARY, Alta. and NEW ORLEANS, June 22, 2022 (GLOBE NEWSWIRE) — Skymount Medical, a drug discovery company using a highly predictive artificial intelligence (AI) platform to repurpose and create innovative new drugs and therapies, announced today that pharmaceutical industry leader Bruce D. Forrest, MD, MBA, joined the Company as Chief Medical Officer.

Advertisement 2

Content of the article

Former Divisional Executive Vice President at Pfizer, Inc. and prior to that, Wyeth Pharmaceuticals, Inc., Bruce D. Forrest, MD, MBA brings more than 30 years of global leadership in pharmaceutical development, with extensive development expertise of vaccines and biopharmaceuticals in both large and emerging markets. He led the clinical activities supporting the marketing authorization of RotaShield® (EU), Prevnar® (Global) and FluMist®, and developed successful strategies for the integration and coordination of development activities across the international scale. See Dr. Forrest’s full biography here.

“Dr. Forrest has earned a reputation for creating innovative solutions to complex product development challenges. His extensive clinical experience and proven leadership will strengthen our efforts and support the progress of our AI platform. We look forward to Dr. Forrest’s insights as we strive to capture the full impact of this very exciting intersection of technology and medicine,” said Zubin Kothawala, President and CEO of Skymount Medical.

Advertisement 3

Content of the article

Dr. Forrest was the founder of BD Forrest & Company, a pharmaceutical industry consulting firm, which was acquired by Hudson Innovations in 2018.

“Skymount Medical’s AI platform has been successful in accelerating every phase of drug discovery. I am thrilled to be part of the team committed to advancing a technology with the potential to revolutionize the way treatments are developed, all with the goal of improving health outcomes and providing access to effective treatments. for patients,” Dr. Forrest said.

About DeepDrug™

The DeepDrug™ artificial intelligence platform was developed by an interdisciplinary team of researchers at Louisiana State University (LSU). The DeepDrug™ Platform utilizes several key components to provide state-of-the-art compound and formula generation capability that dramatically reduces the time and cost associated with traditional drug discovery.

Advertisement 4

Content of the article

About Skymount Medical Inc.

Skymount Medical is an artificial intelligence and biotechnology company that owns the exclusive rights to DeepDrug™️, a patent-pending AI platform, which Skymount Medical uses to accelerate drug discovery and development. Along with Louisiana State University, the company is currently developing combination therapies to fight COVID-19 and all strains of coronavirus. Additionally, Skymount Medical plans to develop treatments for other infectious diseases, new antibiotics for antibiotic-resistant bacteria and other rare indications. Visit skymountmed.com to learn more.

Investor Relations Contact

Lisa M. Wilson, On-Site Communications, Inc.
Such. : 212-452-2793
Email: [email protected]econy.com

Advertisement 1


Postmedia is committed to maintaining a lively yet civil discussion forum and encourages all readers to share their views on our articles. Comments can take up to an hour to be moderated before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications. You will now receive an email if you receive a reply to your comment, if there is an update to a comment thread you follow, or if a user follows you comments. See our Community Guidelines for more information and details on how to adjust your email settings.